Dapagliflozin Tetraacetate

Dapagliflozin Tetraacetate is a medication used to treat type 2 diabetes. It belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs work by blocking the reabsorption of glucose in the kidneys, which leads to increased glucose excretion in the urine and helps lower blood sugar levels. Chemically, Dapagliflozin Tetraacetate is a white to off-white powder that is soluble in water and ethanol. It is a derivative of dapagliflozin, which is the active ingredient in the drug Farxiga. The tetraacetate form is a more stable and easier to handle form of dapagliflozin. The recommended dosage of Dapagliflozin Tetraacetate is 10 mg once daily, taken with or without food. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Common side effects of the medication include urinary tract infections, genital yeast infections, and increased urination. Dapagliflozin Tetraacetate should be used with caution in patients with impaired kidney function, as it can increase the risk of dehydration and kidney damage. It should also be avoided in pregnant or breastfeeding women, as the safety of the medication in these populations has not been established. Overall, Dapagliflozin Tetraacetate is a useful medication for managing type 2 diabetes and can help improve blood sugar control. However, it should only be used under the guidance of a healthcare provider and with careful monitoring of kidney function and potential side effects.